Cyclophilin Inhibitors for Hepatitis C Therapy

Fernando E. Membreno; Jennifer C. Espinales; Eric J. Lawitz

doi:10.1016/j.cld.2012.09.008

Cyclophilin Inhibitors for Hepatitis C Therapy

Fernando E. Membreno, Jennifer C. Espinales, Eric J. Lawitz

Research output: Contribution to journal › Review article › peer-review

18 Scopus citations

Abstract

This article highlights a unique time in the history of Hepatitis C therapy. In the last few years new families of direct-acting antivirals have emerged, that block different viral proteins to interrupt viral replication, such as protease, NS5A inhibitors, and NS5B inhibitors. There are few host-targeted agents in development; currently cyclophilin inhibitors are the only host-targeted agents in advanced development. One of these new agents has now progressed to phase 3 clinical trials; in this review article their potential role as a future therapy to cure Hepatitis C is discussed.

Original language	English (US)
Pages (from-to)	129-139
Number of pages	11
Journal	Clinics in Liver Disease
Volume	17
Issue number	1
DOIs	https://doi.org/10.1016/j.cld.2012.09.008
State	Published - Feb 2013
Externally published	Yes

Keywords

Alisporivir
Cyclophilin
Cyclophilin inhibitors
Debio 025
Interferon-free
NIM 811
Non-interferon
SCY-635

ASJC Scopus subject areas

Hepatology

Access to Document

10.1016/j.cld.2012.09.008

Fingerprint Dive into the research topics of 'Cyclophilin Inhibitors for Hepatitis C Therapy'. Together they form a unique fingerprint.

Cite this

@article{8ce02d6a109241ebb7062ee6a5d05a74,

title = "Cyclophilin Inhibitors for Hepatitis C Therapy",

abstract = "This article highlights a unique time in the history of Hepatitis C therapy. In the last few years new families of direct-acting antivirals have emerged, that block different viral proteins to interrupt viral replication, such as protease, NS5A inhibitors, and NS5B inhibitors. There are few host-targeted agents in development; currently cyclophilin inhibitors are the only host-targeted agents in advanced development. One of these new agents has now progressed to phase 3 clinical trials; in this review article their potential role as a future therapy to cure Hepatitis C is discussed.",

keywords = "Alisporivir, Cyclophilin, Cyclophilin inhibitors, Debio 025, Interferon-free, NIM 811, Non-interferon, SCY-635",

author = "Membreno, {Fernando E.} and Espinales, {Jennifer C.} and Lawitz, {Eric J.}",

year = "2013",

month = feb,

doi = "10.1016/j.cld.2012.09.008",

language = "English (US)",

volume = "17",

pages = "129--139",

journal = "Clinics in Liver Disease",

issn = "1089-3261",

publisher = "W.B. Saunders Ltd",

number = "1",

}

TY - JOUR

T1 - Cyclophilin Inhibitors for Hepatitis C Therapy

AU - Membreno, Fernando E.

AU - Espinales, Jennifer C.

AU - Lawitz, Eric J.

PY - 2013/2

Y1 - 2013/2

N2 - This article highlights a unique time in the history of Hepatitis C therapy. In the last few years new families of direct-acting antivirals have emerged, that block different viral proteins to interrupt viral replication, such as protease, NS5A inhibitors, and NS5B inhibitors. There are few host-targeted agents in development; currently cyclophilin inhibitors are the only host-targeted agents in advanced development. One of these new agents has now progressed to phase 3 clinical trials; in this review article their potential role as a future therapy to cure Hepatitis C is discussed.

AB - This article highlights a unique time in the history of Hepatitis C therapy. In the last few years new families of direct-acting antivirals have emerged, that block different viral proteins to interrupt viral replication, such as protease, NS5A inhibitors, and NS5B inhibitors. There are few host-targeted agents in development; currently cyclophilin inhibitors are the only host-targeted agents in advanced development. One of these new agents has now progressed to phase 3 clinical trials; in this review article their potential role as a future therapy to cure Hepatitis C is discussed.

KW - Alisporivir

KW - Cyclophilin

KW - Cyclophilin inhibitors

KW - Debio 025

KW - Interferon-free

KW - NIM 811

KW - Non-interferon

KW - SCY-635

UR - http://www.scopus.com/inward/record.url?scp=84870051464&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84870051464&partnerID=8YFLogxK

U2 - 10.1016/j.cld.2012.09.008

DO - 10.1016/j.cld.2012.09.008

M3 - Review article

C2 - 23177289

AN - SCOPUS:84870051464

VL - 17

SP - 129

EP - 139

JO - Clinics in Liver Disease

JF - Clinics in Liver Disease

SN - 1089-3261

IS - 1

ER -

Cyclophilin Inhibitors for Hepatitis C Therapy

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this